PathWhiz

PathWhiz ID	Pathway	Meta Data
PW146377 View Pathway	drug action Lesinurad Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 18:03 Last Updated: October 07, 2023 at 18:03
PW127588 View Pathway	drug action Letermovir Action Pathway Homo sapiens Letermovir is an antiviral medication that treats cytomegalovirus (CMV) infections and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant.It was approved by the FDA on November 8, 2017 and is the first of the DNA terminase complex inhibitors for CMV. Cytomegalovirus requires a DNA terminase complex for processing of viral DNA. This complex consists of multiple subunits (pUL51, pUL56, and pUL89). Viral DNA is produced in a single repeating strand which is cut by the DNA terminase complex into individual genomes which can then be packaged into the mature viral particles. Letemovir inhibits the DNA terminase complex, preventing the viral DNA from cutting the DNA and packaging it inside the viral capsid. Thie produces immature, non-infective viruses. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: May 11, 2023 at 12:12 Last Updated: May 11, 2023 at 12:12
PW146491 View Pathway	drug action Letermovir Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 18:19 Last Updated: October 07, 2023 at 18:19
PW176335 View Pathway	metabolic Letermovir Predicted Metabolism Pathway Homo sapiens Metabolites of sildenafil are predicted with biotransformer. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Omolola Created On: December 07, 2023 at 15:13 Last Updated: December 07, 2023 at 15:13
PW145104 View Pathway	drug action Letrozole Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 15:05 Last Updated: October 07, 2023 at 15:05
PW000811 View Pathway	metabolic Leucine Biosynthesis Escherichia coli Leucine biosynthesis involves a five-step conversion process starting with the valine precursor 2-keto-isovalerate interacting with acetyl-CoA and water through a 2-isopropylmalate synthase resulting in Coenzyme A, hydrogen Ion and 2-isopropylmalic acid. The latter compound reacts with isopropylmalate isomerase which dehydrates the compound resulting in a Isopropylmaleate. This compound reacts with water through a isopropylmalate isomerase resulting in 3-isopropylmalate. This compound interacts with a NAD-driven D-malate / 3-isopropylmalate dehydrogenase results in 2-isopropyl-3-oxosuccinate. This compound interacts spontaneously with hydrogen resulting in the release of carbon dioxide and ketoleucine. Ketoleucine interacts in a reversible reaction with L-glutamic acid through a branched-chain amino-acid aminotransferase resulting in Oxoglutaric acid and L-leucine. L-leucine can then be exported outside the cytoplasm through a transporter: L-amino acid efflux transporter. In the final step, ketoleucine can be catalyzed to form L-leucine by branched-chain amino-acid aminotransferase (IlvE) and tyrosine aminotransferase (TryB). L-Glutamic acid can also be transformed into oxoglutaric acid by these two enzymes. Tyrosine aminotransferase can be suppressed by lecuine, and inhibited by 2-keto-isovarlerate and its end product, tyrosine. 2-ketoisocaproate can not be introduced if 2-keto-isovarlerate inhibit TyrB and IlvE is absent. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: miguel ramirez Created On: March 16, 2015 at 15:51 Last Updated: March 16, 2015 at 15:51
PW122595 View Pathway	metabolic Leucine Biosynthesis Pseudomonas aeruginosa Leucine biosynthesis involves a five-step conversion process starting with the valine precursor 2-keto-isovalerate interacting with acetyl-CoA and water through a 2-isopropylmalate synthase resulting in Coenzyme A, hydrogen Ion and 2-isopropylmalic acid. The latter compound reacts with isopropylmalate isomerase which dehydrates the compound resulting in a Isopropylmaleate. This compound reacts with water through a isopropylmalate isomerase resulting in 3-isopropylmalate. This compound interacts with a NAD-driven D-malate / 3-isopropylmalate dehydrogenase results in 2-isopropyl-3-oxosuccinate. This compound interacts spontaneously with hydrogen resulting in the release of carbon dioxide and ketoleucine. Ketoleucine interacts in a reversible reaction with L-glutamic acid through a branched-chain amino-acid aminotransferase resulting in Oxoglutaric acid and L-leucine. L-leucine can then be exported outside the cytoplasm through a transporter: L-amino acid efflux transporter. In the final step, ketoleucine can be catalyzed to form L-leucine by branched-chain amino-acid aminotransferase (IlvE) and tyrosine aminotransferase (TryB). L-Glutamic acid can also be transformed into oxoglutaric acid by these two enzymes. Tyrosine aminotransferase can be suppressed by lecuine, and inhibited by 2-keto-isovarlerate and its end product, tyrosine. 2-ketoisocaproate can not be introduced if 2-keto-isovarlerate inhibit TyrB and IlvE is absent. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ana Marcu Created On: August 12, 2019 at 18:20 Last Updated: August 12, 2019 at 18:20
PW002475 View Pathway	metabolic Leucine Biosynthesis Saccharomyces cerevisiae Leucine biosynthesis involves a five-step conversion process starting with the valine precursor 2-keto-isovalerate interacting with acetyl-CoA and water through a 2-isopropylmalate synthase resulting in Coenzyme A, hydrogen Ion and 2-isopropylmalic acid. The latter compound reacts with isopropylmalate isomerase which dehydrates the compound resulting in a Isopropylmaleate. This compound reacts with water through a isopropylmalate isomerase resulting in 3-isopropylmalate. This compound interacts with a NAD-driven D-malate / 3-isopropylmalate dehydrogenase results in 2-isopropyl-3-oxosuccinate. This compound interacts spontaneously with hydrogen resulting in the release of carbon dioxide and ketoleucine. Ketoleucine interacts in a reversible reaction with L-glutamic acid through a branched-chain amino-acid aminotransferase resulting in Oxoglutaric acid and L-leucine. L-leucine can then be exported outside the cytoplasm through a transporter: L-amino acid efflux transporter. In the final step, ketoleucine can be catalyzed to form L-leucine by branched-chain amino-acid aminotransferase (IlvE) and tyrosine aminotransferase (TryB). L-Glutamic acid can also be transformed into oxoglutaric acid by these two enzymes. Tyrosine aminotransferase can be suppressed by lecuine, and inhibited by 2-keto-isovarlerate and its end product, tyrosine. 2-ketoisocaproate can not be introduced if 2-keto-isovarlerate inhibit TyrB and IlvE is absent. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: miguel ramirez Created On: February 19, 2016 at 13:35 Last Updated: February 19, 2016 at 13:35
PW002540 View Pathway	metabolic Leucine Biosynthesis Arabidopsis thaliana Leucine biosynthesis involves a five-step conversion process starting with the valine precursor 2-keto-isovalerate interacting with acetyl-CoA and water through a 2-isopropylmalate synthase resulting in Coenzyme A, hydrogen Ion and 2-isopropylmalic acid. The latter compound reacts with isopropylmalate isomerase which dehydrates the compound resulting in a Isopropylmaleate. This compound reacts with water through a isopropylmalate isomerase resulting in 3-isopropylmalate. This compound interacts with a NAD-driven D-malate / 3-isopropylmalate dehydrogenase results in 2-isopropyl-3-oxosuccinate. This compound interacts spontaneously with hydrogen resulting in the release of carbon dioxide and ketoleucine. Ketoleucine interacts in a reversible reaction with L-glutamic acid through a branched-chain amino-acid aminotransferase resulting in Oxoglutaric acid and L-leucine. L-leucine can then be exported outside the cytoplasm through a transporter: L-amino acid efflux transporter. In the final step, ketoleucine can be catalyzed to form L-leucine by branched-chain amino-acid aminotransferase (IlvE) and tyrosine aminotransferase (TryB). L-Glutamic acid can also be transformed into oxoglutaric acid by these two enzymes. Tyrosine aminotransferase can be suppressed by lecuine, and inhibited by 2-keto-isovarlerate and its end product, tyrosine. 2-ketoisocaproate can not be introduced if 2-keto-isovarlerate inhibit TyrB and IlvE is absent. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: miguel ramirez Created On: May 05, 2016 at 14:53 Last Updated: May 05, 2016 at 14:53
PW002490 View Pathway	metabolic Leucine Degradation Saccharomyces cerevisiae The degradation of L-leucine starts either in the mitochondria or the cytosol. L-leucine reacts with 2-oxoglutarate through a branch-chain amino acid aminotransferase resulting in the release of ketoleucine and glutamate. The latter compound reacts with ketoisocaproate decarboxylase resulting in the release of carbon dioxide and 3-methylbutanal. The latter compound can then be turned into 3-methylbutanol through a alcohol dehydrogenase BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: miguel ramirez Created On: February 29, 2016 at 14:20 Last Updated: February 29, 2016 at 14:20